Results 81 to 90 of about 19,854 (197)

Contrasting effects of intracellular and extracellular human PCSK9 on inflammation, lipid alteration and cell death

Communications Biology
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is one of the major regulators of low-density lipoprotein receptor (LDLR). Information on role and regulation of PCSK9 in lung is very limited.
Aram Ghalali, Fahd Alhamdan, Swapna Upadhyay, Koustav Ganguly, Kjell Larsson, Lena Palmberg, Mizanur Rahman   +6 more
doaj   +1 more source

Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations

Frontiers in Pharmacology
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily secreted by hepatocytes. PCSK9 is critical in liver low-density lipoprotein receptors (LDLRs) metabolism.
Fengyuan Lu, En Li, Xiaoyu Yang, Xiaoyu Yang   +3 more
doaj   +1 more source

APOE and Cerebral Microbleeds: Insights Into Causal Proteins and Therapeutic Targets

Brain and Behavior, Volume 16, Issue 6, June 2026.
This study identifies APOE as a key causal protein for cerebral microbleeds (CMBs). By integrating Mendelian randomization (MR) and colocalization analysis of the plasma proteome from UKB‐PPP and deCODE datasets, we provide genetic evidence that circulating APOE levels are causally linked to CMB susceptibility. Furthermore, protein–protein interaction (
Lei Yang, Jian‐Lan Zhao, Jie Song, Lin‐Hui Chen, Chun Yu, Qiang Yuan, Gang Wu, Jin Hu, Mei‐Hua Wang   +8 more
wiley   +1 more source

Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice

Frontiers in Pharmacology
InstructionAccumulating evidence has shown that proprotein convertase subtilisin/kexin type 9 (PCSK9) is associated with inflammation in the vascular system. However, the roles of PCSK9 in hepatic inflammation remain unclear.
Xue-Ying Zhang, Qing-Qing Lu, Yan-Jie Li, Shan-Rui Shi, Chao-Nan Ma, Miao Miao, Shou-Dong Guo   +6 more
doaj   +1 more source

Homeobox B13 activates the hypoxia‐inducible factor 1 pathway through histone lactylation thereby reprogramming lipid metabolism and promoting sorafenib resistance in hepatocellular carcinoma

Journal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
Lactylation‐mediated metabolism reprogramming in HCC sorafenib resistance. In sorafenib‐resistant hepatocellular carcinoma (HCC) cells, lactate accumulation drives histone H3 lysine 18 lactylation (H3K18la). This modification is specifically enriched in the promoter region of homeobox B13 (HOXB13), activating HOXB13 transcription and upregulating its ...
Qingqing Xie, Fangxia Teng, Ting Ding, Huaizhe Zhang, Jian Huang, Shu Zhang   +5 more
wiley   +1 more source

ASSOCIATION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN FAMILIAL HYPERCHOLESTEROLEMIA

Атеросклероз, 2019
Objective was to study the levels and the relationship between lipoprotein-associated phospholipase A2 (Lp-PLA2) and proprotein convertase subtilisin/kexin type 9 (PCSK9), their relationship with other lipid parameters in patients with familial ...
K. S. Benimetskaya, V. S. Shramko, E. M. Stakhneva, K. V. Makarenkova, L. V. Shcherbakova, Yu. I. Ragino, M. I. Voevoda   +6 more
doaj   +1 more source

Moderate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis

Clinical Cardiology, Volume 49, Issue 6, June 2026.
ABSTRACT Background High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its ...
Emad Uddin Sajid, Muhammad Hasnain Azeem, Alishba Fatima, Syeda Masooma Jafri, Danish Hassan, Taha Ibrahim, Kashish Zehra Manjee, Syed Rayyan Ahmed, Tooba Ali, Rida Shakeel, Muhammad Usman, Raghabendra Kumar Mahato, Danish Bawa   +12 more
wiley   +1 more source

Sensing and Communicating β‐Cell Stress in the Context of T1D Etiology: New Opportunities for Therapeutic Impact

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
Type 1 diabetes (T1D) results from the immune‐mediated destruction of insulin‐producing pancreatic β‐cells. Recent human studies show that early β‐cell stress maladaptations precede overt immune cell infiltration. DOC2B, a vesicle secretion regulatory protein that supports β‐cell functionality and resilience against stress, declines early in T1D ...
Diana Esparza, Chathurani S. Jayasena, Tijana Jovanovic‐Talisman, Debbie C. Thurmond   +3 more
wiley   +1 more source

The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk

South African Family Practice, 2016
Hypercholesterolaemia and dyslipidaemia, marked by decreased levels of high-density lipoprotein and elevated levels of lowdensity lipoprotein (LDL), increase the risk of cardiovascular disease.
Natalie Schellack, Gustav Schellack, E. Bronkhorst   +2 more
doaj   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1547-1554, June 2026.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source